Rivipansel

GlycoMimetics (NASDAQ: GLYC) announced late Friday afternoon that Pfizer's (NYSE: PFE) Phase 3 clinical trial evaluating Rivipansel in sickle cell disease has not met its primary or key secondary endpoints. On Monday morning, a number of firms have downgraded the stock: Jefferies downgraded...

Large-cap pharma stocks have seen a mixed performance in year to date, and among this group, Pfizer Inc. (NYSE: PFE) is poised to benefit from some key second-half catalysts, according to an analyst at Bank of America Merrill Lynch. The Analyst Jason Gerberry reiterated a Buy rating on Pfizer and...

Cowen and Company has started the coverage of GlycoMimetics Inc (NASDAQ: GLYC) with an Outperform rating on high confidence of success in the Phase 3 data of Pfizer Inc. (NYSE: PFE)-partnered lead candidate Rivipansel for sickle cell vaso-occlusive crises. "We also think wholly owned GMI-1271 has...